These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18271931)

  • 1. Transforming growth factor beta derived from bone matrix promotes cell proliferation of prostate cancer and osteoclast activation-associated osteolysis in the bone microenvironment.
    Sato S; Futakuchi M; Ogawa K; Asamoto M; Nakao K; Asai K; Shirai T
    Cancer Sci; 2008 Feb; 99(2):316-23. PubMed ID: 18271931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoblast-derived factors promote metastatic potential in human prostate cancer cells, in part via non-canonical transforming growth factor β (TGFβ) signaling.
    Karlsson T; Sundar R; Widmark A; Landström M; Persson E
    Prostate; 2018 May; 78(6):446-456. PubMed ID: 29383751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment.
    Thiolloy S; Edwards JR; Fingleton B; Rifkin DB; Matrisian LM; Lynch CC
    PLoS One; 2012; 7(1):e29862. PubMed ID: 22238668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase (MMP)-13 regulates mammary tumor-induced osteolysis by activating MMP9 and transforming growth factor-beta signaling at the tumor-bone interface.
    Nannuru KC; Futakuchi M; Varney ML; Vincent TM; Marcusson EG; Singh RK
    Cancer Res; 2010 May; 70(9):3494-504. PubMed ID: 20406980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.
    Futakuchi M; Nannuru KC; Varney ML; Sadanandam A; Nakao K; Asai K; Shirai T; Sato SY; Singh RK
    Cancer Sci; 2009 Jan; 100(1):71-81. PubMed ID: 19038005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional knockout of PDK1 in osteoclasts suppressed osteoclastogenesis and ameliorated prostate cancer-induced osteolysis in murine model.
    Zhang Y; Nong H; Bai Y; Zhou Q; Zhang Q; Liu M; Liu P; Zeng G; Zong S
    Eur J Med Res; 2023 Oct; 28(1):433. PubMed ID: 37828580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Role for TGFβ Signaling in Preclinical Osteolytic Estrogen Receptor-Positive Breast Cancer Bone Metastases Progression.
    Cheng JN; Frye JB; Whitman SA; Kunihiro AG; Pandey R; Funk JL
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cross-species analysis of a mouse model of breast cancer-specific osteolysis and human bone metastases using gene expression profiling.
    Sadanandam A; Futakuchi M; Lyssiotis CA; Gibb WJ; Singh RK
    BMC Cancer; 2011 Jul; 11():304. PubMed ID: 21774828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
    J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling.
    Verona EV; Elkahloun AG; Yang J; Bandyopadhyay A; Yeh IT; Sun LZ
    Cancer Res; 2007 Jun; 67(12):5737-46. PubMed ID: 17575140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular mechanisms of tumor-bone interactions in osteolytic metastases.
    Chirgwin JM; Guise TA
    Crit Rev Eukaryot Gene Expr; 2000; 10(2):159-78. PubMed ID: 11186331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Morphogenetic Protein-2 Promotes Osteoclasts-mediated Osteolysis via Smad1 and p65 Signaling Pathways.
    Miao X; Yuan J; Wu J; Zheng J; Zheng W; Wang F; Wang C; Li X; Liu S; Shi Z; Li J
    Spine (Phila Pa 1976); 2021 Feb; 46(4):E234-E242. PubMed ID: 33156278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The downregulation of IGFBP3 by TGF-β signaling in oral cancer contributes to the osteoclast differentiation.
    Park J; Jung MJ; Chung WY
    Biochem Biophys Res Commun; 2021 Jan; 534():381-386. PubMed ID: 33256984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoclast-derived matrix metalloproteinase-7, but not matrix metalloproteinase-9, contributes to tumor-induced osteolysis.
    Thiolloy S; Halpern J; Holt GE; Schwartz HS; Mundy GR; Matrisian LM; Lynch CC
    Cancer Res; 2009 Aug; 69(16):6747-55. PubMed ID: 19679556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand.
    Itoh K; Udagawa N; Katagiri T; Iemura S; Ueno N; Yasuda H; Higashio K; Quinn JM; Gillespie MT; Martin TJ; Suda T; Takahashi N
    Endocrinology; 2001 Aug; 142(8):3656-62. PubMed ID: 11459815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
    Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
    Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
    Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
    Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
    Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
    Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and pharmacological activation of Hedgehog signaling inhibits osteoclastogenesis and attenuates titanium particle-induced osteolysis partly through suppressing the JNK/c-Fos-NFATc1 cascade.
    Zhang L; Yang Y; Liao Z; Liu Q; Lei X; Li M; Saijilafu ; Zhang Z; Hong D; Zhu M; Li B; Yang H; Chen J
    Theranostics; 2020; 10(15):6638-6660. PubMed ID: 32550895
    [No Abstract]   [Full Text] [Related]  

  • 20. Tranilast suppresses prostate cancer growth and osteoclast differentiation in vivo and in vitro.
    Sato S; Takahashi S; Asamoto M; Naiki T; Naiki-Ito A; Asai K; Shirai T
    Prostate; 2010 Feb; 70(3):229-38. PubMed ID: 19790239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.